Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714563 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NSD2BRD4NAMPTKDM4A | |
| SCHEMBL13217214 | 0.88 | CCNC (0.44) | NAMPTKCNH2DYRK1AMAPTTDP1 | |
| SCHEMBL30400296 | 0.81 | L3MBTL1 (0.43) | L3MBTL1NSD2BRD4NAMPTKDM4A | |
| SCHEMBL10163771 | 0.81 | L3MBTL1 (0.49) | L3MBTL1BRD4NAMPTKDM4AGLS | |
| SCHEMBL30399922 | 0.81 | L3MBTL1 (0.49) | L3MBTL1BRD4NAMPTKDM4AGLS | |
| SCHEMBL15871964 | 0.81 | BRD4 (0.49) | L3MBTL1BRD4NAMPTKDM4AGLS | |
| SCHEMBL9298255 | 0.81 | EGLN2 (0.44) | L3MBTL1MAPTHDAC1NPSR1 | |
| SCHEMBL2586677 | 0.81 | L3MBTL1 (0.52) | L3MBTL1NSD2NAMPTCTSSCTSK | |
| SCHEMBL337888 | 0.80 | L3MBTL1 (0.48) | L3MBTL1BRD4NAMPTKDM4AGLS | |
| SCHEMBL14200095 | 0.80 | LMNA (0.52) | L3MBTL1BRD4NAMPTKDM4AGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428044-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| US-20170101391-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101391-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| WO-2015193339-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2225238-B1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2225238-B1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8552205-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552205-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2225238-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
| US-6117880-A | TREATMENT OF DIABETES, RETINOPATHY, RESTINOSIS, ACROMEGALY, AND DEPRESSION | MERCK & CO., INC. (US) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101391-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BUB1, BUB1B, AURKB | L3MBTL1 1750/4885NSD2 2808/4885BRD4 318/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | L3MBTL1 4566/4885NSD2 3560/4885BRD4 421/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | L3MBTL1 4566/4885NSD2 3560/4885BRD4 421/4885 |
| US-10428044-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | BUB1, BUB1B, AURKB | L3MBTL1 1750/4885NSD2 2808/4885BRD4 318/4885 |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | L3MBTL1 3059/4885NSD2 4237/4885BRD4 579/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | L3MBTL1 4566/4885NSD2 3560/4885BRD4 421/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | L3MBTL1 4566/4885NSD2 3560/4885BRD4 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.